Temoporfin (m-THPC)
(Synonyms: 替莫泊芬; m-THPC; KW2345) 目录号 : GC32774
A light-activated chlorin
Cas No.:122341-38-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Temoporfin is a synthetic chlorin with light-
1.Alian, W., Andersson-Engels, S., Svanberg, K., et al.Laser-induced fluorescence studies of meso-tetra(hydroxyphenyl)chlorin in malignant and normal tissues in ratsBr. J. Cancer70(5)880-885(1994) 2.Ris, H.B., Altermatt, H.J., Inderbitzi, R., et al.Photodynamic therapy with chlorins for diffuse malignant mesothelioma: Initial clinical resultsBr. J. Cancer64(6)1116-1120(1991) 3.Reshetov, V., Lassalle, H.P., Fran?ois, A., et al.Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): Comparison of treatment efficacy and distribution characteristics in vivoInt. J. Nanomedicine83817-3831(2013) 4.Succo, G., Rosso, S., Fadda, G.L., et al.Salvage photodynamic therapy for recurrent nasopharyngeal carcinomaPhotodiagnosis Photodyn.Ther.11(2)63-70(2014)
| Cas No. | 122341-38-2 | SDF | |
| 别名 | 替莫泊芬; m-THPC; KW2345 | ||
| Canonical SMILES | OC1=CC=CC(/C2=C3CCC(/C(C4=CC(O)=CC=C4)=C5C=C/C(N/5)=C(C6=CC(O)=CC=C6)/C(C=C/7)=NC7=C(C8=CC(O)=CC=C8)/C9=CC=C2N9)=N\3)=C1 | ||
| 分子式 | C44H32N4O4 | 分子量 | 680.75 |
| 溶解度 | DMSO : ≥ 30 mg/mL (44.07 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.469 mL | 7.3448 mL | 14.6897 mL |
| 5 mM | 0.2938 mL | 1.469 mL | 2.9379 mL |
| 10 mM | 0.1469 mL | 0.7345 mL | 1.469 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Temoporfin (Foscan®, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)--a second-generation photosensitizer
Photochem Photobiol 2011 Nov-Dec;87(6):1240-96.PMID:21848905DOI:10.1111/j.1751-1097.2011.00986.x.
This review traces the development and study of the second-generation photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin through to its acceptance and clinical use in modern photodynamic (cancer) therapy. The literature has been covered up to early 2011.
Redistribution of meta-tetra(hydroxyphenyl)chlorin (m-THPC) from conventional and PEGylated liposomes to biological substrates
Photochem Photobiol Sci 2011 Jun;10(6):911-9.PMID:21311777DOI:10.1039/c0pp00303d.
We used the phenomenon of previously described photoinduced fluorescence quenching and fluorescence polarization to evaluate the transfer of meta-tetra(hydroxyphenyl)chlorin (m-THPC) from commercial high-drug load liposomes to plasma proteins and model membranes. Fluorescence quenching of m-THPC in liposomes by iodide indicates that part of m-THPC in PEGylated liposomes is localized in the PEG shell, while the rest is bound to the lipid bilayer. It was shown that the two molecule pools in the commercial PEGylated liposomal formulation Fospeg® condition the characteristics of the m-THPC release kinetics. A substantial percentage of m-THPC from Fospeg® is released much faster than from the conventional liposomal formulation Foslip®. Using the technique of resonance light scattering, it was shown that partial m-THPC aggregation is present in liposomes with very high drug loads, higher in PEGylated liposomes compared to conventional ones.
In vitro effects and localisation of the photosensitizers m-THPC and m-THPC MD on carcinoma cells of the human breast (MCF-7) and Chinese hamster fibroblasts (V-79)
Lasers Surg Med 1997;20(4):443-50.PMID:9142685DOI:10.1002/(sici)1096-9101(1997)20:4<443::aid-lsm11>3.0.co;2-c.
Background and objective: Photodynamic therapy (PDT) is the combination of a photosensitizer with laser light to induce preferential destruction of malignant cells. In this study two new photosensitizers--5,10,15,20-meta-tetra(hydroxyphenyl) chlorin (m-THPC) and m-THPC MethoxyPEG2000 derivative (m-THPC MD)--were tested, both for their dark toxicity, i.e., cytotoxicity in the absence of light, and for their light-induced cytotoxicity in mammalian cell cultures. Study design/materials and methods: Cell lines used were MCF-7 (human breast carcinoma) and V-79 (Chinese hamster lung fibroblast). After cultivation under standard conditions, cells were administered the photosensitizers and 24 hr later exposed to various energy levels of laser light at a wavelength of 652 nm. Cell survival was monitored using a clonogenic assay and was expressed as the surviving fraction of the untreated control. Results: Up to an m-THPC concentration of 1 microgram/ml, no dark toxicity was observed; at higher concentrations a rapid fall in survival occurred. m-THPC MD showed no dark toxicity up to 100 micrograms/ml. In vitro m-THPC was approximately 10 times more cytotoxic than m-THPC MD. The MCF-7 and V-79 cell lines displayed similar responses to PDT. Conclusions: Both m-THPC and m-THPC MD are very efficient photosensitizers in vitro. Up to the therapeutic dose, neither exhibited dark toxicity. There is clinical relevance of the photosensitizers by a large therapeutic index.
Photodynamic therapy effect of m-THPC (Foscan) in vivo: correlation with pharmacokinetics
Br J Cancer 2003 Jul 21;89(2):398-404.PMID:12865935DOI:10.1038/sj.bjc.6601101.
m-Tetra(hydroxyphenyl)chlorin (m-THPC, Foscan, Temoporfin) has an unusually high photodynamic efficacy which cannot be explained by its photochemical properties alone. In vivo interactions are therefore of critical importance in determining this high potency. The pharmacokinetics of m-THPC in a rat tumour model was determined using (14)C m-THPC in an LSBD(1) fibrosarcoma implanted into BDIX rats. The photodynamic therapy (PDT) efficacy was determined at different drug administrations to light intervals and correlated with the tumour and plasma pharmacokinetic data. The plasma pharmacokinetics of m-THPC can be interpreted by compartmental analysis as having three half-lives of 0.46, 6.91 and 82.5 h, with a small initial volume of distribution, suggesting retention in the vascular compartment. Tissues of the reticuloendothelial system showed high accumulation of m-THPC, particularly the liver. PDT efficacy of m-THPC over the same time course seemed to exhibit two peaks of activity (2 and 24 h), in terms of tumour growth delay with the peak at 24 h postinjection correlating to the maximum tumour concentration. Investigation on tumour cells isolated from m-THPC-treated tumours suggested that the peak PDT activity at 2 h represents an effect on the vasculature while the peak at 24 h shows a more direct response. These results indicate that the in vivo PDT effect of m-THPC occurs via several mechanisms.
Characterization by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry of the major photoproducts of Temoporfin (m-THPC) and bacteriochlorin (m-THPBC)
J Mass Spectrom 2001 Jul;36(7):825-31.PMID:11473406DOI:10.1002/jms.186.
The photobleaching of 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin (temoporfin, m-THPC) and 5,10,15,20-tetrakis(m-hydroxyphenyl)bacteriochlorin (bacteriochlorin, m-THPBC) was studied in ethanol-water (1 : 99, v/v) and in physiological medium (phosphate-buffered saline, PBS) with or without fetal calf serum (FCS). m-THPC solution was irradiated with the laser radiation of 650 nm, whereas m-THPBC solution underwent two consecutive irradiations at 532 and 650 nm. The photoproducts were characterized by UV-visible absorption spectrophotometry and by matrix-assisted laser desorption/ionization (MALDI) coupled with Fourier transform ion cyclotron resonance mass spectrometry (FTICRMS). Independent of the solvent used, the phototransformation of either photosensitizer yielded the formation of 5,10,15,20-tetrakis (m-hydroxyphenyl)porphyrin (m-THPP) through a major dehydrogenation process.